Clinical trials: fluorouracil
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Recurrent Colon Cancer, Recurrent Rectal Cancer
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
This randomized phase III trial is studying giving irinotecan and cetuximab together with bevacizumab to see how well it works compared with giving irinotecan and cetuximab alone in treating patients with metastatic colorectal…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT00499369
- Testing
- irinotecan hydrochloride, leucovorin calcium, fluorouracil
- Where
- 382 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
This study involves the use of Oxaliplatin, 5-Fluorouracil (5-FU), Leucovorin and Cetuximab, which are all medicines approved by the Food and Drug Administration (FDA) and are commercially available.
- Trial name
- NCT00580073
- Testing
- FOLFOX4, Cetuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Gastrointestinal Cancer
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects from chemotherapy agents.
- Trial name
- IMPACT-GI (NCT04736472)
- Testing
- Pharmacogenetic test
- Where
- 3 sites in United States
- Volunteers
- 552 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who…
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
- Trial name
- NCT00096278
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 2,710 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%)…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03073785
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer.
- Trial name
- NCT00433550
- Testing
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Where
- 115 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Breast Cancer
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in…
- Trial name
- NCT02120417
- Testing
- Ruxolitinib, Capecitabine
- Where
- 106 sites in United States, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Stomach Neoplasms, Advanced Gastric Cancer
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced…
- Trial name
- NCT00842244
- Testing
- axitinib, capecitabine, cisplatin
- Where
- 5 sites in Japan, South Korea
- Volunteers
- 22 people
- Sponsor
- Pfizer
Ductal Adenocarcinoma of Pancreas, Adenocarcinoma of Ampulla
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable…
- Trial name
- NCT02626520
- Testing
- Gemcitabine and nanoparticle albumin bound paclitaxel, 5-fluorouracil and irinotecan, Preoperative chemoradiation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Essentia Health
Breast Cancer
Phase II Neoadjuvant in Inflammatory Breast Cancer
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to…
- Trial name
- NCT00756470
- Testing
- Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Squamous Cell Carcinoma of the Head and Neck
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic…
- Trial name
- CHANGE (NCT01177956)
- Testing
- Cetuximab, Cisplatin, 5-Fluorouracil
- Where
- 14 sites in China, South Korea
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colon Cancer
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches.
- Trial name
- FANG-CLM (NCT01505166)
- Testing
- Vigil™ Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gradalis, Inc.
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
This is a prospective, randomized, double-blind phase II trial to evaluate the efficacy and safety of two doses of vitamin D supplementation in combination with standard chemotherapy in participants with previously-untreated…
- Trial name
- NCT01516216
- Testing
- FOLFOX + bevacizumab, Vitamin D
- Where
- 18 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute